MUltiple Sclerosis and Extract of Cannabis (MUSEC): a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis (MS)

http://isrctn.org/> ◽

10.1186/isrctn42223114 ◽

2012 ◽

Author(s):

John Zajicek

Keyword(s):

Multiple Sclerosis ◽

Cannabis Sativa ◽

Symptomatic Relief ◽

Muscle Stiffness ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

Yearbook of Medicine ◽

10.1016/s0084-3873(09)79327-7 ◽

2009 ◽

Vol 2009 ◽

pp. 63-64

Author(s):

B. Hutton

Keyword(s):

Ankylosing Spondylitis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

10.1016/s0140-6736(08)60454-7 ◽

2008 ◽

Vol 371 (9617) ◽

pp. 998-1006 ◽

Author(s):

Shumpei Yokota ◽

Tomoyuki Imagawa ◽

Masaaki Mori ◽

Takako Miyamae ◽

Yukoh Aihara ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Download Full-text

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

Arthritis & Rheumatism ◽

10.1002/art.23969 ◽

2008 ◽

Vol 58 (11) ◽

pp. 3402-3412 ◽

Author(s):

Robert D. Inman ◽

John C. Davis ◽

Désirée Van Der Heijde ◽

Laura Diekman ◽

Joachim Sieper ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4507 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4507-4507 ◽

Author(s):

W. Vervenne ◽

J. Bennouna ◽

Y. Humblet ◽

S. Gill ◽

M. J. Moore ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase

Download Full-text

Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5504 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5504-5504 ◽

Author(s):

Christian Kurzeder ◽

Isabel Bover ◽

Frederik Marmé ◽

Joern Rau ◽

Patricia Pautier ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Platinum Resistant

Download Full-text

The efficacy and safety of the biosimilar interferon beta-1a Teberif® in patients with relapsing-remitting multiple sclerosis: data from a comparative international multicenter double-blind placebo-controlled randomized Phase III study

10.26226/morressier.59a3e8b6d462b8028d895371 ◽

2017 ◽

Author(s):

Camila Tursunova

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Phase Iii Study ◽

Relapsing Remitting Multiple Sclerosis ◽

International Multicenter

Download Full-text